Back to Search
Start Over
The case for measuring anti-drug antibodies in people with multiple sclerosis
- Source :
- Expert review of clinical immunology. 10(6)
- Publication Year :
- 2014
-
Abstract
- The advent of biopharmaceuticals (BPs) has led to significant improvements in the treatment of many chronic inflammatory diseases, and the number of BPs on the market and of diseases treated reflects their success. However, repetitive parenteral administration and intrinsic immunogenic properties of the drug can elicit an immune response, leading to production of anti-drug antibodies (ADA). This is a major limitation of the use of BPs and has to be taken into consideration in clinical practice and during drug development. With increasing knowledge about the immunogenicity of BPs and regular ADA testing in patients, we ensure optimized long-term treatment for the individual and thus optimal use of health care resources. This field has already been extensively investigated in the treatment of multiple sclerosis with IFN-β, but there is a clear need for consensus from academia, health care providers and the BP industry in managing ADA across all BPs and diseases.
- Subjects :
- Drug
medicine.medical_specialty
Multiple Sclerosis
media_common.quotation_subject
Immunology
Portraits as Topic
urologic and male genital diseases
Antibodies
Health care
Immunology and Allergy
Medicine
Humans
Immunologic Factors
In patient
Intensive care medicine
media_common
biology
business.industry
Immunogenicity
Multiple sclerosis
Interferon-beta
medicine.disease
Clinical Practice
Drug development
biology.protein
Antibody
business
hormones, hormone substitutes, and hormone antagonists
Subjects
Details
- ISSN :
- 17448409
- Volume :
- 10
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Expert review of clinical immunology
- Accession number :
- edsair.doi.dedup.....ffd3e1c3779346138656a6a3b96df888